Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-D-glucose

Molecular Cancer Therapeutics

Volumn 6, Issue 2, 2007, Pages 732-741

  Maher, Johnathan C ^a   Wangpaichitr, Medhi ^a   Savaraj, Niramol ^a,b   Kurtoglu, Metin ^a   Lampidis, Theodore J ^a  

^a UNIVERSITY OF MIAMI   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; DEOXYGLUCOSE; DOXORUBICIN; FLUORODEOXYGLUCOSE; FRUCTOSE BISPHOSPHATE ALDOLASE; GLUCOSE 6 PHOSPHATE ISOMERASE; GLYCOLYTIC ENZYME; HEXOKINASE; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LACTATE DEHYDROGENASE; LACTIC ACID; OLIGOMYCIN; OXAMIC ACID; SMALL INTERFERING RNA; STAUROSPORINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL HYPOXIA; CELL MUTANT; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SENSITIVITY; GLYCOLYSIS; HUMAN; HUMAN CELL; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN FUNCTION;

ADENOSINE TRIPHOSPHATE; ANTIMETABOLITES; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL HYPOXIA; DEOXYGLUCOSE; DRUG RESISTANCE, NEOPLASM; GLUCOSE-6-PHOSPHATE ISOMERASE; GLYCOLYSIS; HELA CELLS; HEXOKINASE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOBLOTTING; LACTIC ACID; LIVER NEOPLASMS; PLASMIDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSFECTION;

EID: 33847353815     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0407     Document Type: Article

References (41)

1. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical biologic, and molecular aspects. J Natl Cancer Inst 2001;93:266-76.
2. Vaupel P, Thaws O, Hoeckel M. Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol 2001;18:243-59.
3. Liu H, Hu YP, Savaraj N, Priebe W, Lampidis TJ. Hypersensitization of tumor cells to glycolytic inhibitors. Biochemistry 2001;40:5542-7.
4. Liu H, Savaraj N, Priebe W, Lampidis TJ. Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: a strategy for solid tumor therapy (Model C). Biochem Pharmacol 2002;64:1745-51.
5. Maher JC, Krishan A, Lampidis TJ. Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-D-glucose in tumor cells treated under hypoxic vs aerobic conditions. Cancer Chemother Pharmacol 2004;53:116-22.
6. Maher JC, Savaraj N, Priebe W, Liu H, Lampidis TJ. Differential sensitivity to 2-deoxy-D-glucose between two pancreatic cell lines correlates with GLUT-1 expression. Pancreas 2005;30:e34-9.
7. Maschek G, Savaraj N, Priebe W, et al. 2-DeoXy-D-glucose increases the efficacy of Adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res 2004;64:31-4.
8. Schaider H, Haberkorn U, Petru E, Berger MR. Combination treatment based on metabolic effects of dinaline. J Cancer Res Clin Oncol 1995;12: 203-10.
9. 2 tension. Proc Natl Aced Sci U S A 1995;92:5510-4.
10. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Aced Sci U S A 1993;90:4304-8.
11. Bertino JR, Carman MD, Weiner HL, et al. Gene amplification and altered enzymes as mechanisms for the development of drug resistance. Cancer Treat Rep 1983;67:901-4.
12. Greijer AE, van der Wall E. The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol 2004;57:1009-14.
13. Piret JP, Mottet D, Raes M, Michiels C. Is HIF-1 alpha a pro-or an anti-apoptotic protein? Biochem Pharmacol 2002;64:889-92.
14. Krishan A, Paika K, Frei E III. Cytofluorometric studies on the action of podophyllotoxin and epipodophyllotoxins (VM-26, VP-16-213) on the cell cycle traverse of human lymphoblasts. J Cell Biol 1975;66:521-30.
15. Stroke DM, Burkhardt T, Desbaillets I, et al. HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. FASEB J 2001;15:2445-53.
16. Shams I, Avivi A, Nevo E. Hypoxic stress tolerance of the blind subterranean mole rat: expression of erythropoietin and hypoxia-inducible factor 1 alpha. Proc Natl Acad Sci U S A 2004;101:9698-703.
17. Haddad JJ, Land SC. A non-hypoxic, ROS-sensitive pathway mediates TNF-alpha-dependent regulation of HIF-1alpha. FEES Lett 2001;505:269-74.
18. Funasaka T, Yanagawa T, Hogan V, Raz A. Regulation of phosphoglucose isomerase/autocrine motility factor expression by hypoxia. FASEB J 2005;19:1422-30.
19. Lampidis TJ, Kurtoglu M, Maher JC, et al. Efficacy of 2-halogen substituted D-glucose analogs in blocking glycolysis and killing "hypoxic tumor cells." Cancer Chemother Pharmacol 2006 Dec; 58:725-34. Epub 2006 Mar 23.
20. Schaaff I, Heinisch J, Zimmermann FK. Overproduction of glycolytic enzymes in yeast. Yeast 1989;5:285-90.
21. Wood SM, Gleadle JM, Pugh CW, Hankinson O, Ratcliffe PJ. The role of the aryl hydrocarbon receptor nuclear translocator (ARNT) in hypoxic induction of gene expression. Studies in ARNT-deficient cells. J Biol Chem 1996;271:15117-23.
22. Vaux EC, Matzen E, Yeates KM, Ratcliffe PJ. Regulation of hypoxia-inducible factor is preserved in the absence of a functioning mitochondrial respiratory chain. Blood 2001;98:296-302.
23. Tatsumi T, Shiraishi J, Keira N, et al. Intracellular ATP is required for mitochondrial apoptotic pathways in isolated hypoxic rat cardiac myocytes. Cardiovasc Res 2003;59:428-40.
24. Unruh A, Ressel A, Mohamed HG, et al. The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 2003;22: 3213-20.
25. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-32.
26. Semenza GL, Roth PH, Fang HM, Wang GL. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 1994;269:23757-63.
27. Crane RK, Sols A. The non-competitive inhibition of brain hexokinase by glucose-6-phosphate and related compounds. J Biol Chem 1954;210: 597-606.
28. Wick AN, Drury DR, Nakada HI, Wolfe JB. Localization of the primary metabolic block produced by 2-deoxyglucose. J Biol Chem 1957;224: 963-9.
29. Chandramouli V, Carter JR, Jr. Metabolic effects of 2-deoxy-D-glucose in isolated fat cells. Biochim Biophys Acta 1977;496:278-91.
30. Manuel y Keenoy B, Zahner D, Malaisse WJ. Dissociated effects of 2-deoxy-D-glucose on D-[2 -3H]glucose and D-[5-3H]glucose conversion into 3HOH in rat erythrocytes. Biochem J 1992;288:433-8.
31. 31PNMR and metabolic implications. Biochimie 1992;74:867-73.
32. Seagroves TN, Ryan HE, Lu H, et al. Transcription factor HIF-1 is a necessary mediator of the Pasteur effect in mammalian cells. Mol Cell Biol 2001;21:3436-44.
33. Scopes RK. Studies with a reconstituted muscle glycolytic system. The rate and extent of glycolysis in simulated post-mortem conditions. Biochem J 1974;142:79-86.
34. Hofmeyr JS, Cornish-Bowden A. Regulating the cellular economy of supply and demand. FEBS Lett 2000;476:47-51.
35. Hankinson O. Single-step selection of clones of a mouse hepatoma line deficient in aryl hydrocarbon hydroxylase. Proc Natl Acad Sci U S A 1979;76:373-6.
36. Maxwell PH, Ratcliffe PJ. Oxygen sensors and angiogenesis. Semin Cell Dev Biol 2002;73:29-37.
37. Pugh CW. Oxygen sensing in cancer. Ann Mad 2003;35:380-90.
38. Chen J, Zhao S, Nakada K, et al. Dominant-negative hypoxia-inducible factor-1 alpha reduces tumorigenicity of pancreatic cancer cells through the suppression of glucose metabolism. Am J Pathol 2003;162: 1283-91.
39. Maxwell PH. The HIF pathway in cancer. Semin Cell Dev Biol 2005; 16:523-30.
40. Escuin D, Simons JW, Giannakakou P. Exploitation of the HIF axis for cancer therapy. Cancer Biol Ther 2004;3:608-11.
41. Rapisarda A, Shoemaker RH, Melillo G. Targeting topoisomerase I to inhibit hypoxia inducible factor 1. Cell Cycle 2004;3:172-5.